The Prognostic Impact of Comorbidities in Patients with De-Novo Diffuse Large B-Cell Lymphoma Treated with R-CHOP Immunochemotherapy in Curative Intent.
CCI
DLBCL
HCT-CI
R-CHOP
comorbidities
prognosis
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
02 Apr 2020
02 Apr 2020
Historique:
received:
21
03
2020
revised:
29
03
2020
accepted:
31
03
2020
entrez:
8
4
2020
pubmed:
8
4
2020
medline:
8
4
2020
Statut:
epublish
Résumé
Patient-related factors, namely comorbidities, impact the clinical outcome of patients with diffuse large B-cell lymphoma (DLBCL). The prevalence and prognostic impact of comorbidities were examined using the validated scores Charlson Comorbidity Index (CCI) and Hematopoietic Cell Transplantation-specific Comorbidity Index (HCT-CI) in 181 patients with DLBCL at initial diagnosis before treatment with rituximab, cyclophosphamide, vincristine, doxorubicin and prednisone (R-CHOP). Pronounced comorbidities as defined by CCI and HCT-CI scoring of ≥2 were detected in 9.9% and 28.2% of patients, respectively, and occurred more frequently at advanced age ( This study demonstrates the prognostic relevance of comorbidities classified by CCI and HCT-CI in patients with DLBCL undergoing curative treatment with R-CHOP. A structured evaluation of comorbidities might refine prognostication alongside currently used prognostic parameters, namely age, and should be evaluated in prospective trials.
Sections du résumé
BACKGROUND
BACKGROUND
Patient-related factors, namely comorbidities, impact the clinical outcome of patients with diffuse large B-cell lymphoma (DLBCL).
METHODS
METHODS
The prevalence and prognostic impact of comorbidities were examined using the validated scores Charlson Comorbidity Index (CCI) and Hematopoietic Cell Transplantation-specific Comorbidity Index (HCT-CI) in 181 patients with DLBCL at initial diagnosis before treatment with rituximab, cyclophosphamide, vincristine, doxorubicin and prednisone (R-CHOP).
RESULTS
RESULTS
Pronounced comorbidities as defined by CCI and HCT-CI scoring of ≥2 were detected in 9.9% and 28.2% of patients, respectively, and occurred more frequently at advanced age (
CONCLUSION
CONCLUSIONS
This study demonstrates the prognostic relevance of comorbidities classified by CCI and HCT-CI in patients with DLBCL undergoing curative treatment with R-CHOP. A structured evaluation of comorbidities might refine prognostication alongside currently used prognostic parameters, namely age, and should be evaluated in prospective trials.
Identifiants
pubmed: 32252438
pii: jcm9041005
doi: 10.3390/jcm9041005
pmc: PMC7230391
pii:
doi:
Types de publication
Journal Article
Langues
eng
Déclaration de conflit d'intérêts
R.S.: Celgene: Honoraria, Membership in an entity’s Board of Directors or advisory committees; Novartis: Honoraria, Membership in an entity’s Board of Directors or advisory committees; Teva: Research funding. All other authors declare no conflict of interests.
Références
Br J Haematol. 2014 May;165(4):489-96
pubmed: 24754632
Blood. 2006 Jan 1;107(1):265-76
pubmed: 16150940
J Geriatr Oncol. 2020 Jan;11(1):41-54
pubmed: 31416716
N Engl J Med. 2002 Jan 24;346(4):235-42
pubmed: 11807147
Ann Oncol. 2018 Mar 1;29(3):544-562
pubmed: 29194473
J Natl Compr Canc Netw. 2008 Oct;6(9):927-34
pubmed: 18926101
Ann Hematol. 2018 Feb;97(2):267-276
pubmed: 29130134
J Geriatr Oncol. 2015 Sep;6(5):346-52
pubmed: 26116168
Oncologist. 2018 Jun;23(6):722-729
pubmed: 29317552
Am J Hematol. 2017 Oct;92(10):989-996
pubmed: 28612386
Ann Oncol. 1997 Oct;8(10):973-8
pubmed: 9402170
J Clin Oncol. 2008 Jan 1;26(1):54-9
pubmed: 18165640
Blood. 2014 Feb 6;123(6):837-42
pubmed: 24264230
BMC Cancer. 2016 Dec 1;16(1):932
pubmed: 27908282
Biol Blood Marrow Transplant. 2005 Sep;11(9):713-20
pubmed: 16125642
J Clin Oncol. 1999 Apr;17(4):1244
pubmed: 10561185
Blood. 2004 Aug 1;104(3):634-41
pubmed: 15016643
Lancet Oncol. 2011 May;12(5):460-8
pubmed: 21482186
J Clin Oncol. 2005 Jun 20;23(18):4117-26
pubmed: 15867204
Blood. 2007 Mar 1;109(5):1857-61
pubmed: 17105812
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Cancer Epidemiol. 2015 Dec;39(6):1103-12
pubmed: 26341588
J Clin Oncol. 2006 Jul 1;24(19):3121-7
pubmed: 16754935
J Intern Med. 2019 Apr;285(4):455-468
pubmed: 30368947
Leuk Res. 2014 Mar;38(3):275-83
pubmed: 24439052
Blood. 2005 Oct 15;106(8):2912-9
pubmed: 15994282
J Intern Med. 2019 Jun;285(6):681-692
pubmed: 30811713
J Cancer Res Clin Oncol. 2011 Jul;137(7):1079-84
pubmed: 21221637
J Clin Oncol. 2007 Feb 10;25(5):579-86
pubmed: 17242396
Ann Hematol. 2012 Sep;91(9):1383-91
pubmed: 22526364
JAMA. 2011 Nov 2;306(17):1874-83
pubmed: 22045765
Clin Oncol (R Coll Radiol). 2014 Oct;26(10):648-52
pubmed: 24929649
Cancer. 2019 Jun 1;125(11):1837-1847
pubmed: 30707765
J Clin Oncol. 2018 Aug 1;36(22):2326-2347
pubmed: 29782209
Lancet Haematol. 2017 Jan;4(1):e46-e55
pubmed: 28041583
Ann Hematol. 2008 May;87(5):429-30
pubmed: 18299833
J Clin Oncol. 1990 Jun;8(6):963-77
pubmed: 2348230
Ann Oncol. 2015 Jun;26(6):1058-68
pubmed: 25635006
Ann Oncol. 2015 Sep;26 Suppl 5:v116-25
pubmed: 26314773
Lancet Oncol. 2008 Feb;9(2):105-16
pubmed: 18226581
J Geriatr Oncol. 2019 May;10(3):497-503
pubmed: 30241779
Blood. 2012 Aug 9;120(6):1327-33
pubmed: 22740454
Anticancer Res. 2014 May;34(5):2559-64
pubmed: 24778077
N Engl J Med. 1993 Sep 30;329(14):987-94
pubmed: 8141877
J Geriatr Oncol. 2015 Mar;6(2):141-52
pubmed: 25491101